Nitrosodimethylamine (NDMA) contamination in ranitidine and metformin raised global health concerns.
NDMA is classified as a probable human carcinogen, leading to recalls and regulatory reviews.
The presence of this impurity in medications is closely monitored to ensure drug safety.